Systematic approaches to identify E3 ligase Substrates

Biochemical Journal

Volumn 473, Issue 22, 2016, Pages 4083-4101

  Iconomou, Mary ^a,b   Saunders, Darren N ^b  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEASOME; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3; UBIQUITIN PROTEIN LIGASE;

BIOCHEMISTRY; CONTROLLED STUDY; DRUG DEVELOPMENT; ENZYME ANALYSIS; ENZYME SUBSTRATE; FUNCTIONAL GENOMICS; HUMAN; HUMAN GENOME; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; UBIQUITINATION; VALIDATION STUDY; ANIMAL; ENZYME SPECIFICITY; METABOLISM; PROCEDURES; PROTEIN DEGRADATION; PROTEIN PROCESSING; PROTEOMICS;

ANIMALS; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOLYSIS; PROTEOMICS; SUBSTRATE SPECIFICITY; UBIQUITIN; UBIQUITIN-PROTEIN LIGASES;

EID: 85009348465     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BCJ20160719     Document Type: Review

References (134)

1. Chau, V., Tobias, J.W., Bachmair, A., Marriott, D., Ecker, D.J., Gonda, D.K. et al. (1989) A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein. Science 243, 1576-1583 PMID:2538923.
2. Haglund, K., Sigismund, S., Polo, S., Szymkiewicz, I., Di Fiore, P.P., Dikic, I. et al. (2003) Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation. Nat. Cell. Biol. 5, 461-466 doi:10.1038/ncb983.
3. Hicke, L. and Riezman, H. (1996) Ubiquitination of a yeast plasma membrane receptor signals its ligand-stimulated endocytosis. Cell 84, 277-287 doi:10.1016/S0092-8674(00)80982-4.
4. Staub, O., Gautschi, I., Ishikawa, T., Breitschopf, K., Ciechanover, A., Schild, L. et al. (1997) Regulation of stability and function of the epithelial Na+ channel (ENaC) by ubiquitination. EMBO J. 16, 6325-6336 doi:10.1093/emboj/16.21.6325.
5. Koepp, D.M., Harper, J.W. and Elledge, S.J. (1999) How the cyclin became a cyclin: Regulated proteolysis in the cell cycle. Cell 97, 431-434 doi:http://dx.doi.org/10.1016/S0092-8674(00)80753-9.
6. Jin, L., Williamson, A., Banerjee, S., Philipp, I. and Rape, M. (2008) Mechanism of ubiquitin-chain formation by the human anaphase-promoting complex. Cell 133, 653-665 doi:10.1016/j.cell.2008.04.012.
7. Spence, J., Sadis, S., Haas, A.L. and Finley, D. (1995) A ubiquitin mutant with specific defects in DNA repair and multiubiquitination. Mol. Cell. Biol. 15, 1265-1273 doi:10.1128/MCB.15.3.1265.
8. Davies, A.A., Huttner, D., Daigaku, Y., Chen, S. and Ulrich, H.D. (2008) Activation of ubiquitin-dependent DNA damage bypass is mediated by replication protein A. Mol. Cell 29, 625-636 doi:10.1016/j.molcel.2007.12.016.
9. Wu, L., Li, L., Zhou, B., Qin, Z. and Dou, Y. (2014) H2b ubiquitylation promotes RNA Pol II processivity via PAF1 and pTEFb. Mol. Cell 54, 920-931 doi:10.1016/j.molcel.2014.04.013.
10. Gudjonsson, T., Altmeyer, M., Savic, V., Toledo, L., Dinant, C., Grøfte, M. et al. (2012) TRIP12 and UBR5 suppress spreading of chromatin ubiquitylation at damaged chromosomes. Cell 150, 697-709 doi:10.1016/j.cell.2012.06.039.
11. Yoshida, M., Yoshida, K., Kozlov, G., Lim, N.S., De Crescenzo, G., Pang, Z. et al. (2006) Poly(A) binding protein (PABP) homeostasis is mediated by the stability of its inhibitor, Paip2. EMBO J. 25, 1934-1944 doi:10.1038/sj.emboj.7601079.
12. Cleynen, I., Vazeille, E., Artieda, M., Verspaget, H.W., Szczypiorska, M., Bringer, M.-A. et al. (2014) Genetic and microbial factors modulating the ubiquitin proteasome system in inflammatory bowel disease. Gut 63, 1265-1274 doi:10.1136/gutjnl-2012-303205.
13. Komander, D. and Rape, M. (2012) The ubiquitin code. Annu. Rev. Biochem. 81, 203-229 doi:10.1146/annurev-biochem-060310-170328.
14. Jung, C.-R., Hwang, K.-S., Yoo, J., Cho, W.-K., Kim, J.-M., Kim, W.H. et al. (2006) E2-EPF UCP targets pVHL for degradation and associates with tumor growth and metastasis. Nat. Med. 12, 809-816 doi:10.1038/nm1440.
15. Zhou, Q., Wang, H., Schwartz, D.M., Stoffels, M., Park, Y.H., Zhang, Y. et al. (2015) Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. Nat. Genet. 48, 67-73 doi:10.1038/ng.3459.
16. Tan, Z., Sun, X., Hou, F.-S., Oh, H.-W., Hilgenberg, L.G.W., Hol, E.M. et al. (2007) Mutant ubiquitin found in Alzheimer's disease causes neuritic beading of mitochondria in association with neuronal degeneration. Cell Death Differ. 14, 1721-1732 doi:10.1038/sj.cdd.4402180.
17. Chesarino, N.M., McMichael, T.M. and Yount, J.S. (2015) E3 ubiquitin ligase NEDD4 promotes influenza virus infection by decreasing levels of the antiviral protein IFITM3. PLoS Pathog. 11, e1005095 doi:10.1371/journal.ppat.1005095.
18. Hershko, A. and Ciechanover, A. (1992) The ubiquitin system for protein degradation. Annu. Rev. Biochem. 61, 761-807 doi:10.1146/annurev.bi.61.070192.003553.
19. Bernassola, F., Karin, M., Ciechanover, A. and Melino, G. (2008) The HECT family of E3 ubiquitin ligases: multiple players in cancer development. Cancer Cell 14, 10-21 doi:10.1016/j.ccr.2008.06.001.
20. Rotin, D. and Kumar, S. (2009) Physiological functions of the HECT family of ubiquitin ligases. Nat. Rev. Mol. Cell. Biol. 10, 398-409 doi:10.1038/nrm2690.
21. Dove, K.K., Stieglitz, B., Duncan, E.D., Rittinger, K. and Klevit, R.E. (2016) Molecular insights into RBR E3 ligase ubiquitin transfer mechanisms. EMBO Rep. 17, 1221-1235 doi:10.15252/embr.201642641.
22. Qiu, J., Sheedlo, M.J., Yu, K., Tan, Y., Nakayasu, E.S., Das, C. et al. (2016) Ubiquitination independent of E1 and E2 enzymes by bacterial effectors. Nature 533, 120-124 doi:10.1038/nature17657.
23. Siepmann, T.J., Bohnsack, R.N., Tokgoz, Z., Baboshina, O.V. and Haas, A.L. (2003) Protein interactions within the N-end rule ubiquitin ligation pathway. J. Biol. Chem. 278, 9448-9457 doi:10.1074/jbc.M211240200.
24. Lee, I. and Schindelin, H. (2008) Structural insights into E1-catalyzed ubiquitin activation and transfer to conjugating enzymes. Cell 134, 268-278 doi:10.1016/j.cell.2008.05.046.
25. Christensen, D.E. and Klevit, R.E. (2009) Dynamic interactions of proteins in complex networks: identifying the complete set of interacting E2s for functional investigation of E3-dependent protein ubiquitination. FEBS J. 276, 5381-5389 doi:10.1111/j.1742-4658.2009.07249.x.
26. Nijman, S.M.B., Luna-Vargas, M.P.A., Velds, A., Brummelkamp, T.R., Dirac, A.M.G., Sixma, T.K. et al. (2005) A genomic and functional inventory of deubiquitinating enzymes. Cell 123, 773-786 doi:10.1016/j.cell.2005.11.007.
27. Metzger, M.B., Hristova, V.A. and Weissman, A.M. (2012) HECT and RING finger families of E3 ubiquitin ligases at a glance. J. Cell. Sci. 125, 531-537 doi:10.1242/jcs.091777.
28. Nalepa, G., Rolfe, M. and Harper, J.W. (2006) Drug discovery in the ubiquitin-proteasome system. Nat. Rev. Drug Discov. 5, 596-613 doi:10.1038/nrd2056.
29. Kee, Y., Lyon, N. and Huibregtse, J.M. (2005) The Rsp5 ubiquitin ligase is coupled to and antagonized by the Ubp2 deubiquitinating enzyme. EMBO J. 24, 2414-2424 doi:10.1038/sj.emboj.7600710.
30. Rutz, S., Kayagaki, N., Phung, Q.T., Eidenschenk, C., Noubade, R., Wang, X. et al. (2014) Deubiquitinase DUBA is a post-Translational brake on interleukin-17 production in T cells. Nature 518, 417-421 doi:10.1038/nature13979.
31. Xie, Y., Avello, M., Schirle, M., McWhinnie, E., Feng, Y., Bric-Furlong, E. et al. (2013) Deubiquitinase FAM/USP9X interacts with the E3 ubiquitin ligase SMURF1 protein and protects it from ligase activity-dependent self-degradation. J. Biol. Chem. 288, 2976-2985 doi:10.1074/jbc.M112.430066.
32. Chen, D., Frezza, M., Schmitt, S., Kanwar, J. and Dou, Q.P. (2011) Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr. Cancer Drug Targets 11, 239-253 PMID:21247388.
33. Hoeller, D. and Dikic, I. (2009) Targeting the ubiquitin system in cancer therapy. Nature 458, 438-444 doi:10.1038/nature07960.
34. Mattern, M.R., Wu, J. and Nicholson, B. (2012) Ubiquitin-based anticancer therapy: carpet bombing with proteasome inhibitors vs surgical strikes with E1, E2, E3, or DUB inhibitors. Biochim. Biophys. Acta, Mol. Cell Res. 1823, 2014-2021 doi:10.1016/j.bbamcr.2012.05.005.
35. Pal, A., Young, M.A. and Donato, N.J. (2014) Emerging potential of therapeutic targeting of ubiquitin-specific proteases in the treatment of cancer. Cancer Res. 74, 4955-4966 doi:10.1158/0008-5472.CAN-14-1211.
36. Adams, J., Palombella, V.J., Sausville, E.A., Johnson, J., Destree, A., Lazarus, D.D. et al. (1999) Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res. 59, 2615-2622 PMID:10363983.
37. Goldberg, A.L. (2012) Development of proteasome inhibitors as research tools and cancer drugs. J. Cell. Biol. 199, 583-588 doi:10.1083/jcb.201210077.
38. Orlowski, R.Z., Stinchcombe, T.E., Mitchell, B.S., Shea, T.C., Baldwin, A.S., Stahl, S. (2002) Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J. Clin. Oncol. 20, 4420-4427 doi:10.1200/JCO.2002.01.133.
39. Ocio, E.M., Richardson, P.G., Rajkumar, S.V., Palumbo, A., Mateos, M.V., Orlowski, R. et al. (2014) New drugs and novel mechanisms of action in multiple myeloma in 2013: A report from the International Myeloma Working Group (IMWG). Leukemia 28, 525-542 doi:10.1038/leu.2013.350.
40. Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y. et al. (2010) Identification of a primary target of thalidomide teratogenicity. Science 327, 1345-1350 doi:10.1126/science.1177319.
41. Zhu, Y.X., Braggio, E., Shi, C.-X., Bruins, L.A., Schmidt, J.E., Van Wier, S. et al. (2011) Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 118, 4771-4779 doi:10.1182/blood-2011-05-356063.
42. Sackton, K.L., Dimova, N., Zeng, X., Tian, W., Zhang, M., Sackton, T.B. et al. (2014) Synergistic blockade of mitotic exit by two chemical inhibitors of the APC/C. Nature 514, 646-649 doi:10.1038/nature13660.
43. Liang, Q., Dexheimer, T.S., Zhang, P., Rosenthal, A.S., Villamil, M.A., You, C. et al. (2014) A selective USP1-UAF1 inhibitor links deubiquitination to DNA damage responses. Nat. Chem. Biol. 10, 298-304 doi:10.1038/nchembio.1455.
44. Zhang, W., Wu, K.-P., Sartori, M.A., Kamadurai, H.B., Ordureau, A., Jiang, C. et al. (2016) System-wide modulation of HECT E3 ligases with selective ubiquitin variant probes. Mol. Cell 62, 121-136 doi:10.1016/j.molcel.2016.02.005.
45. Ernst, A., Avvakumov, G., Tong, J., Fan, Y., Zhao, Y., Alberts, P. et al. (2013) A strategy for modulation of enzymes in the ubiquitin system. Science 339, 590-595 doi:10.1126/science.1230161.
46. Obrist, F., Manic, G., Kroemer, G., Vitale, I. and Galluzzi, L. (2015) Trial watch: proteasomal inhibitors for anticancer therapy. Mol. Cell. Oncol. 2, e974463 doi:10.4161/23723556.2014.974463.
47. Zhang, W. and Sidhu, S.S. (2014) Development of inhibitors in the ubiquitination cascade. FEBS Lett. 588, 356-367 doi:10.1016/j.febslet.2013.11.003.
48. Ofir-Rosenfeld, Y., Boggs, K., Michael, D., Kastan, M.B. and Oren, M. (2008) Mdm2 regulates p53 mRNA translation through inhibitory interactions with ribosomal protein L26. Mol. Cell 32, 180-189 doi:10.1016/j.molcel.2008.08.031.
49. Oliner, J.D., Pietenpol, J.A., Thiagalingam, S., Gyuris, J., Kinzler, K.W., Vogelstein, B. et al. (1993) Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362, 857-860 doi:10.1038/362857a0.
50. Roth, J., Dobbelstein, M., Freedman, D.A., Shenk, T. and Levine, A.J. (1998) Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J. 17, 554-564 doi:10.1093/emboj/17.2.554.
51. Vassilev, L.T., Vu, B.T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z. et al. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848 doi:10.1126/science.1092472.
52. Hird, A.W., Aquila, B.M., Hennessy, E.J., Vasbinder, M.M. and Yang, B. (2015) Small molecule inhibitor of apoptosis proteins antagonists: A patent review. Expert Opin. Ther. Pat. 25, 755-774 doi:10.1517/13543776.2015.1041922.
53. Tasaki, T., Mulder, L.C.F., Iwamatsu, A., Lee, M.J., Davydov, I.V., Varshavsky, A. et al. (2005) A family of mammalian E3 ubiquitin ligases that contain the UBR box motif and recognize N-degrons. Mol. Cell. Biol. 25, 7120-7136 doi:10.1128/MCB.25.16.7120-7136.2005.
54. Jadhav, T., Geetha, T., Jiang, J. and Wooten, M.W. (2008) Identification of a consensus site for TRAF6/p62 polyubiquitination. Biochem. Biophys. Res. Commun. 371, 521-524 doi:10.1016/j.bbrc.2008.04.138.
55. Chen, H.I. and Sudol, M. (1995) The WW domain of Yes-Associated protein binds a proline-rich ligand that differs from the consensus established for Src homology 3-binding modules. Proc. Natl Acad. Sci. USA 92, 7819-7823 PMID:7644498.
56. Deckert, M., Elly, C., Altman, A. and Liu, Y.-C. (1998) Coordinated regulation of the tyrosine phosphorylation of Cbl by Fyn and Syk tyrosine kinases. J. Biol. Chem. 273, 8867-8874 doi:10.1074/jbc.273.15.8867.
57. Jiang, W., Wang, S., Xiao, M., Lin, Y., Zhou, L., Lei, Q. et al. (2011) Acetylation regulates gluconeogenesis by promoting PEPCK1 degradation via recruiting the UBR5 ubiquitin ligase. Mol. Cell 43, 33-44 doi:10.1016/j.molcel.2011.04.028.
58. Komander, D., Reyes-Turcu, F., Licchesi, J.D.F., Odenwaelder, P., Wilkinson, K.D., Barford, D. et al. (2009) Molecular discrimination of structurally equivalent Lys 63-linked and linear polyubiquitin chains. EMBO Rep. 10, 466-473 doi:10.1038/embor.2009.55.
59. Pierce, N.W., Kleiger, G., Shan, S.-o. and Deshaies, R.J. (2009) Detection of sequential polyubiquitylation on a millisecond timescale. Nature 462, 615-619 doi:10.1038/nature08595.
60. Yoshida, Y., Saeki, Y., Murakami, A., Kawawaki, J., Tsuchiya, H., Yoshihara, H. et al. (2015) A comprehensive method for detecting ubiquitinated substrates using TR-TUBE. Proc. Natl Acad. Sci. USA 112, 4630-4635 doi:10.1073/pnas.1422313112.
61. Jain, A.K. and Barton, M.C. (2009) Regulation of p53: TRIM24 enters the RING. Cell Cycle 8, 3668-3674 doi:10.4161/cc.8.22.9979.
62. Harper, J.W. and Tan, M.-K.M. (2012) Understanding cullin-RING E3 biology through proteomics-based substrate identification. Mol. Cell. Proteomics 11, 1541-1550 doi:10.1074/mcp.R112.021154.
63. Swatek, K.N. and Komander, D. (2016) Ubiquitin modifications. Cell. Res. 26, 399-422 doi:10.1038/cr.2016.39.
64. Buetow, L. and Huang, D.T. (2016) Structural insights into the catalysis and regulation of E3 ubiquitin ligases. Nat. Rev. Mol. Cell. Biol. doi:10.1038/nrm.2016.91.
65. Kim, W., Bennett, E.J., Huttlin, E.L., Guo, A., Li, J., Possemato, A. et al. (2011) Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol. Cell 44, 325-340 doi:10.1016/j.molcel.2011.08.025.
66. Wagner, S.A., Beli, P., Weinert, B.T., Nielsen, M.L., Cox, J., Mann, M. et al. (2011) A proteome-wide, quantitative survey of in vivo ubiquitylation sites reveals widespread regulatory roles. Mol. Cell. Proteomics 10, M111.013284 doi:10.1074/mcp.M111.013284.
67. Komander, D. (2009) The emerging complexity of protein ubiquitination. Biochem. Soc. Trans. 37, 937-953 doi:10.1042/BST0370937.
68. Ordureau, A., Munch, C. and Harper, J.W. (2015) Quantifying ubiquitin signaling. Mol. Cell 58, 660-676 doi:10.1016/j.molcel.2015.02.020.
69. Sylvestersen, K.B., Young, C. and Nielsen, M.L. (2013) Advances in characterizing ubiquitylation sites by mass spectrometry. Curr. Opin. Chem. Biol. 17, 49-58 doi:10.1016/j.cbpa.2012.12.009.
70. Guo, Z.G., Song, E., Ma, S., Wang, X., Gao, S., Shao, C. et al. (2012) Proteomics strategy to identify substrates of LNX, a PDZ domain-containing E3 ubiquitin ligase. J. Proteome Res. 11, 4847-4862 doi:10.1021/Pr300674c.
71. Bex, C., Knauth, K., Dambacher, S. and Buchberger, A. (2007) A yeast two-hybrid system reconstituting substrate recognition of the von Hippel-Lindau tumor suppressor protein. Nucleic Acids Res. 35, e142 doi:10.1093/nar/gkm932.
72. Murillas, R., Simms, K.S., Hatakeyama, S., Weissman, A.M. and Kuehn, M.R. (2002) Identification of developmentally expressed proteins that functionally interact with Nedd4 ubiquitin ligase. J. Biol. Chem. 277, 2897-2907 doi:10.1074/jbc.M110047200.
73. Kishi, T., Ikeda, A., Koyama, N., Fukada, J. and Nagao, R. (2008) A refined two-hybrid system reveals that SCFCdc4-dependent degradation of Swi5 contributes to the regulatory mechanism of S-phase entry. Proc. Natl Acad. Sci. USA 105, 14497-14502 doi:10.1073/pnas.0806253105.
74. Fortier, J.M. and Kornbluth, J. (2006) NK lytic-Associated molecule, involved in NK cytotoxic function, is an E3 ligase. J. Immunol. 176, 6454-6463 doi:10.4049/jimmunol.176.11.6454.
75. Locke, M., Tinsley, C.L., Benson, M.A. and Blake, D.J. (2009) TRIM32 is an E3 ubiquitin ligase for dysbindin. Hum. Mol. Genet. 18, 2344-2358 doi:10.1093/hmg/ddp167.
76. Guo, Z., Wang, X., Li, H. and Gao, Y. (2013) Screening E3 substrates using a live phage display library. PLoS ONE 8, e76622 doi:10.1371/journal.pone.0076622.
77. Kus, B., Gajadhar, A., Stanger, K., Cho, R., Sun, W., Rouleau, N. et al. (2005) A high throughput screen to identify substrates for the ubiquitin ligase Rsp5. J. Biol. Chem. 280, 29470-29478 doi:10.1074/jbc.M502197200.
78. Gupta, R., Kus, B., Fladd, C., Wasmuth, J., Tonikian, R., Sidhu, S. et al. (2007) Ubiquitination screen using protein microarrays for comprehensive identification of Rsp5 substrates in yeast. Mol. Syst. Biol. 3, 116 doi:10.1038/msb4100159.
79. Lu, J.-y., Lin, Y.-y., Qian, J., Tao, S.-c., Zhu, J., Pickart, C. et al. (2007) Functional dissection of a HECT ubiquitin E3 ligase. Mol. Cell. Proteomics 7, 35-45 doi:10.1074/mcp.M700353-MCP200.
80. Persaud, A., Alberts, P., Amsen, E.M., Xiong, X., Wasmuth, J., Saadon, Z. et al. (2009) Comparison of substrate specificity of the ubiquitin ligases Nedd4 and Nedd4-2 using proteome arrays. Mol. Syst. Biol. 5, 333 doi:10.1038/msb.2009.85.
81. Andrews, P.S., Schneider, S., Yang, E., Michaels, M., Chen, H., Tang, J. et al. (2010) Identification of substrates of SMURF1 ubiquitin ligase activity utilizing protein microarrays. Assay Drug Dev. Technol. 8, 471-487 doi:10.1089/adt.2009.0264.
82. Loch, C.M., Eddins, M.J. and Strickler, J.E. (2011) Protein microarrays for the identification of Praja1 E3 ubiquitin ligase substrates. Cell Biochem. Biophys. 60, 127-135 doi:10.1007/s12013-011-9180-x.
83. Yen, H.-C.S. and Elledge, S.J. (2008) Identification of SCF ubiquitin ligase substrates by global protein stability profiling. Science 322, 923-929 doi:10.1126/science.1160462.
84. Emanuele, M.J., Elia, A.E.H., Xu, Q., Thoma, C.R., Izhar, L., Leng, Y. et al. (2011) Global identification of modular cullin-RING ligase substrates. Cell 147, 459-474 doi:10.1016/j.cell.2011.09.019.
85. Benanti, J.A., Cheung, S.K., Brady, M.C. and Toczyski, D.P. (2007) A proteomic screen reveals SCFGrr1 targets that regulate the glycolytic-gluconeogenic switch. Nat. Cell. Biol. 9, 1184-1191 doi:10.1038/ncb1639.
86. Burande, C.F., Heuze, M.L., Lamsoul, I., Monsarrat, B., Uttenweiler-Joseph, S., Lutz, P. G. et al. (2009) A label-free quantitative proteomics strategy to identify E3 ubiquitin ligase substrates targeted to proteasome degradation. Mol. Cell. Proteomics 8, 1719-1727 doi:10.1074/mcp.M800410-MCP200.
87. Hör, S., Ziv, T., Admon, A. and Lehner, P.J. (2009) Stable isotope labeling by amino acids in cell culture and differential plasma membrane proteome quantitation identify new substrates for the MARCH9 transmembrane E3 ligase. Mol. Cell. Proteomics 8, 1959-1971 doi:10.1074/mcp.M900174-MCP200.
88. Mark, K.G., Simonetta, M., Maiolica, A., Seller, C.A. and Toczyski, D.P. (2014) Ubiquitin ligase trapping identifies an SCFSaf1 pathway targeting unprocessed vacuolar/lysosomal proteins. Mol. Cell 53, 148-161 doi:10.1016/j.molcel.2013.12.003.
89. Tan, M.-K.M., Lim, H.-J., Bennett, E.J., Shi, Y. and Harper, J.W. (2013) Parallel SCF adaptor capture proteomics reveals a role for SCFFBXL17 in NRF2 activation via BACH1 repressor turnover. Mol. Cell 52, 9-24 doi:10.1016/j.molcel.2013.08.018.
90. Kim, T.Y., Siesser, P.F., Rossman, K.L., Goldfarb, D., Mackinnon, K., Yan, F. et al. (2015) Substrate trapping proteomics reveals targets of the βTrCP2/FBXW11 ubiquitin ligase. Mol. Cell. Biol. 35, 167-181 doi:10.1128/MCB.00857-14.
91. Song, M., Hakala, K., Weintraub, S.T. and Shiio, Y. (2011) Quantitative proteomic identification of the BRCA1 ubiquitination substrates. J. Proteome Res. 10, 5191-5198 doi:10.1021/pr200662b.
92. Low, T.Y., Peng, M., Magliozzi, R., Mohammed, S., Guardavaccaro, D., Heck, A.J.R. et al. (2014) A systems-wide screen identifies substrates of the SCF TrCP ubiquitin ligase. Sci. Signal. 7, 8 doi:10.1126/scisignal.2005882.
93. Rubel, C.E., Schisler, J.C., Hamlett, E.D., DeKroon, R.M., Gautel, M., Alzate, O. et al. (2013) Diggin0 on U(biquitin): A novel method for the identification of physiological E3 ubiquitin ligase substrates. Cell. Biochem. Biophys. 67, 127-138 doi:10.1007/s12013-013-9624-6.
94. Mark, K.G., Loveless, T.B. and Toczyski, D.P. (2016) Isolation of ubiquitinated substrates by tandem affinity purification of E3 ligase-polyubiquitin-binding domain fusions (ligase traps). Nat. Protoc. 11, 291-301 doi:10.1038/nprot.2016.008.
95. O'Connor, H.F., Lyon, N., Leung, J.W., Agarwal, P., Swaim, C.D., Miller, K.M. et al. (2015) Ubiquitin-Activated interaction traps (UBAITs) identify E3 ligase binding partners. EMBO Rep. 16, 1699-1712 doi:10.15252/embr.201540620.
96. Coyaud, E., Mis, M., Laurent, E.M.N., Dunham, W.H., Couzens, A.L., Robitaille, M. et al. (2015) BioID-based identification of Skp Cullin F-box (SCF)β-TrCP1/2 E3 ligase substrates. Mol. Cell. Proteomics 14, 1781-1795 doi:10.1074/mcp.M114.045658.
97. Zhuang, M., Guan, S., Wang, H., Burlingame, A.L. and Wells, J.A. (2013) Substrates of IAP ubiquitin ligases identified with a designed orthogonal E3 ligase, the NEDDylator. Mol. Cell 49, 273-282 doi:10.1016/j.molcel.2012.10.022.
98. Sarraf, S.A.., Raman, M., Guarani-Pereira, V., Sowa, M.E., Huttlin, E.L., Gygi, S.P. et al. (2013) Landscape of the PARKIN-dependent ubiquitylome in response to mitochondrial depolarization. Nature 496, 372-376 doi:10.1038/nature12043.
99. Theurillat, J.-P.P., Udeshi, N.D., Errington, W.J., Svinkina, T., Baca, S.C., Pop, M. et al. (2014) Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Science 346, 85-89 doi:10.1126/science.1250255.
100. Lee, K.A., Hammerle, L.P., Andrews, P.S., Stokes, M.P., Mustelin, T., Silva, J.C. et al. (2011) Ubiquitin ligase substrate identification through quantitative proteomics at both the protein and peptide levels. J. Biol. Chem. 286, 41530-41538 doi:10.1074/jbc.M111.248856.
101. Thompson, J.W., Nagel, J., Hoving, S., Gerrits, B., Bauer, A., Thomas, J.R. et al. (2014) Quantitative Lys-?-Gly-Gly (diGly) proteomics coupled with inducible RNAi reveals ubiquitin-mediated proteolysis of DNA damage-inducible transcript 4 (DDIT4) by the E3 ligase HUWE1. J. Biol. Chem. 289, 28942-28955 doi:10.1074/jbc.M114.573352.
102. Mokhonova, E.I., Avliyakulov, N.K., Kramerova, I., Kudryashova, E., Haykinson, M.J., Spencer, M.J. et al. (2015) The E3 ubiquitin ligase TRIM32 regulates myoblast proliferation by controlling turnover of NDRG2. Hum. Mol. Genet. 24, 2873-2883 doi:10.1093/hmg/ddv049.
103. Spinner, C.A., Uttenweiler-Joseph, S., Metais, A., Stella, A., Burlet-Schiltz, O., Moog-Lutz, C. et al. (2015) Substrates of the ASB2α E3 ubiquitin ligase in dendritic cells. Sci. Rep. 5, 16269 doi:10.1038/srep16269.
104. Fields, S. and Song, O.-k. (1989) A novel genetic system to detect protein-protein interactions. Nature 340, 245-246 doi:10.1038/340245a0.
105. Formstecher, E., Aresta, S., Collura, V., Hamburger, A., Meil, A., Trehin, A. et al. (2005) Protein interaction mapping: A Drosophila case study. Genome Res. 15, 376-384 doi:10.1101/gr.2659105.
106. Rual, J.-F., Venkatesan, K., Hao, T., Hirozane-Kishikawa, T., Dricot, A., Li, N. et al. (2005) Towards a proteome-scale map of the human protein-protein interaction network. Nature 437, 1173-1178 doi:10.1038/nature04209.
107. Uetz, P., Fields, S., Giot, L., Cagney, G., Mansfield, T.A., Judson, R.S. et al. (2000) A comprehensive analysis of protein-protein interactions in Saccharomyces cerevisiae. Nature 403, 623-627 doi:10.1038/35001009.
108. Guo, Z., Song, E., Ma, S., Wang, X., Gao, S., Shao, C. et al. (2012) Proteomics strategy to identify substrates of LNX, a PDZ domain-containing E3 ubiquitin ligase. J. Proteome Res. 11, 4847-4862 doi:10.1021/pr300674c.
109. Deane, C.M., Salwinski, L., Xenarios, I. and Eisenberg, D. (2002) Protein interactions: Two methods for assessment of the reliability of high throughput observations. Mol. Cell Proteomics 1, 349-356 PMID:12118076.
110. Edwards, A.M., Kus, B., Jansen, R., Greenbaum, D., Greenblatt, J., Gerstein, M. et al. (2002) Bridging structural biology and genomics: Assessing protein interaction data with known complexes. Trends Genet. 18, 529-536 doi:10.1016/S0168-9525(02)02763-4.
111. Huang, H., Jedynak, B.M. and Bader, J.S. (2007) Where have all the interactions gone? Estimating the coverage of two-hybrid protein interaction maps. PLoS Comput. Biol. 3, e214 doi:10.1371/journal.pcbi.0030214.
112. Rouleau, N., Turcotte, S., Mondou, M.H., Roby, P. and Bosse, R. (2003) Development of a versatile platform for nuclear receptor screening using AlphaScreen™. J. Biomol. Screen 8, 191-197 doi:10.1177/1087057103252605.
113. Afanassiev, V., Hanemann, V. and Wolfl, S. (2000) Preparation of DNA and protein micro arrays on glass slides coated with an agarose film. Nucleic Acids Res. 28, E66 PMID:10871389.
114. Zhu, H., Snyder, M., Klemic, J.F., Chang, S., Bertone, P., Casamayor, A. et al. (2000) Analysis of yeast protein kinases using protein chips. Nat. Genet. 26, 283-289 doi:10.1038/81576.
115. Sutandy, F.X., Qian, J., Chen, C.S. and Zhu, H. (2013) Overview of protein microarrays. Curr. Protoc. Protein Sci. 72:27.1:27.1.1-27.1.16. doi:10.1002/0471140864.ps2701s72.
116. Yen, H.C.-S., Xu, Q., Chou, D.M., Zhao, Z. and Elledge, S.J. (2008) Global protein stability profiling in mammalian cells. Science 322, 918-923 doi:10.1126/science.1160489.
117. Heuze, M.L., Lamsoul, I., Baldassarre, M., Lad, Y., Leveque, S., Razinia, Z. et al. (2008) ASB2 targets filamins A and B to proteasomal degradation. Blood 112, 5130-5140 doi:10.1182/blood-2007-12-128744.
118. Ohta, A., Schumacher, F.-R., Mehellou, Y., Johnson, C., Knebel, A., Macartney, T.J. et al. (2013) The CUL3-KLHL3 E3 ligase complex mutated in Gordon's hypertension syndrome interacts with and ubiquitylates WNK isoforms: disease-causing mutations in KLHL3 and WNK4 disrupt interaction. Biochem. J. 451, 111-122 doi:10.1042/BJ20121903.
119. Sowa, M.E., Bennett, E.J., Gygi, S.P. and Harper, J.W. (2009) Defining the human deubiquitinating enzyme interaction landscape. Cell 138, 389-403 doi:10.1016/j.cell.2009.04.042.
120. Hjerpe, R., Aillet, F., Lopitz-Otsoa, F., Lang, V., England, P., Rodriguez, M.S. et al. (2009) Efficient protection and isolation of ubiquitylated proteins using tandem ubiquitin-binding entities. EMBO Rep. 10, 1250-1258 doi:10.1038/embor.2009.192.
121. Lopitz-Otsoa, F., Rodriguez-Suarez, E., Aillet, F., Casado-Vela, J., Lang, V., Matthiesen, R. et al. (2012) Integrative analysis of the ubiquitin proteome isolated using tandem ubiquitin binding entities (TUBEs). J. Proteomics 75, 2998-3014 doi:10.1016/j.jprot.2011.12.001.
122. Shi, Y., Chan, D.W., Jung, S.Y., Malovannaya, A., Wang, Y., Qin, J. et al. (2011) A data set of human endogenous protein ubiquitination sites. Mol. Cell. Proteomics 10, M110.002089 doi:10.1074/mcp.M110.002089.
123. Raasi, S., Varadan, R., Fushman, D. and Pickart, C.M. (2005) Diverse polyubiquitin interaction properties of ubiquitin-Associated domains. Nat. Struct., Mol. Biol. 12, 708-714 doi:10.1038/nsmb962.
124. Sims, J.J., Haririnia, A., Dickinson, B.C., Fushman, D. and Cohen, R.E. (2009) Avid interactions underlie the Lys63-linked polyubiquitin binding specificities observed for UBA domains. Nat. Struct., Mol. Biol. 16, 883-889 doi:10.1038/nsmb.1637.
125. Xu, G., Paige, J.S. and Jaffrey, S.R. (2010) Global analysis of lysine ubiquitination by ubiquitin remnant immunoaffinity profiling. Nat. Biotechnol. 28, 868-873 doi:10.1038/nbt.1654.
126. Udeshi, N.D., Mani, D.R., Eisenhaure, T., Mertins, P., Jaffe, J.D., Clauser, K.R. et al. (2012) Methods for quantification of in vivo changes in protein ubiquitination following proteasome and deubiquitinase inhibition. Mol. Cell. Proteomics 11, 148-159 doi:10.1074/mcp.M111.016857.
127. Udeshi, N.D., Svinkina, T., Mertins, P., Kuhn, E., Mani, D.R., Qiao, J.W. et al. (2013) Refined preparation and use of anti-diglycine remnant (K- -GG) antibody enables routine quantification of 10, 000s of ubiquitination sites in single proteomics experiments. Mol. Cell. Proteomics 12, 825-831 doi:10.1074/mcp.O112.027094.
128. Rogne, M. and Tasken, K. (2013) Cell signalling analyses in the functional genomics era. New Biotechnol. 30, 333-338 doi:10.1016/j.nbt.2013.01.003.
129. Carlson, S.M. and Gozani, O. (2014) Emerging technologies to map the protein methylome. J. Mol. Biol. 426, 3350-3362 doi:10.1016/j.jmb.2014.04.024.
130. Zhang, K., Tian, S. and Fan, E. (2013) Protein lysine acetylation analysis: current MS-based proteomic technologies. Analyst 138, 1628-1636 doi:10.1039/c3an36837h.
131. Zhang, D. and Zhang, D.E. (2011) Interferon-stimulated gene 15 and the protein ISGylation system. J. Interferon Cytokine Res. 31, 119-130 doi:10.1089/jir.2010.0110.
132. Rabut, G. and Peter, M. (2008) Function and regulation of protein neddylation. 'Protein modifications: beyond the usual suspects' review series. EMBO Rep. 9, 969-976 doi:10.1038/embor.2008.183.
133. Iwabuchi, M., Sheng, H., Thompson, J.W., Wang, L., Dubois, L.G., Gooden, D. et al. (2014) Characterization of the ubiquitin-modified proteome regulated by transient forebrain ischemia. J. Cereb. Blood Flow Metab. 34, 425-432 doi:10.1038/jcbfm.2013.210.
134. Persaud, A., Alberts, P., Hayes, M., Guettler, S., Clarke, I., Sicheri, F. et al. (2011) Nedd4-1 binds and ubiquitylates activated FGFR1 to control its endocytosis and function. EMBO J. 30, 3259-3273 doi:10.1038/emboj.2011.234.